• Biosynex's wholly owned subsidiary Chembio Diagnostic Systems secured $5.7 million in BARDA funding to develop its DPP Biothreat Panel.
• The 20-month program targets a rapid point-of-care test for pathogens causing plague, tularemia and melioidosis.
• Chembio will seek FDA clearance for the panel, which remains under development and is not commercially available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosynex SA published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.